特集: 調査項目の変更・追加が可能なセミカスタムオーダー型の調査レポート(Lucintel社)はこちら

特集 : 国別の市場調査レポートをお探しの方はこちら

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

非結核性抗酸菌症 (NTM) - 疫学予測:2030年

Nontuberculous Mycobacteria Infection (NTM) - Epidemiology forecast 2030

発行 DelveInsight Business Research LLP 商品コード 923585
出版日 ページ情報 英文 100 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=108.13円で換算しております。
非結核性抗酸菌症 (NTM) - 疫学予測:2030年 Nontuberculous Mycobacteria Infection (NTM) - Epidemiology forecast 2030
出版日: 2020年02月01日 ページ情報: 英文 100 Pages
概要

主要7ヶ国 (米国、ドイツ、スペイン、イタリア、フランス、英国、日本) の非結核性抗酸菌症 (NTM) の患者集団は、2017年~2030年のCAGRで0.6%の成長が予測されています。

当レポートでは、世界の非結核性抗酸菌症 (NTM) 治療薬市場について調査分析し、疾患の背景、疫学、主要7ヶ国の市場動向について、体系的な情報を提供しています。

目次

第1章 主な考察

第2章 エグゼクティブサマリー

第3章 非結核性抗酸菌症 (NTM) :感染症市場の概要

  • 2017年:NTM感染症の患者シェア (%) 分布
  • 2030年:NTM感染症の患者シェア (%) 分布

第4章 非結核性抗酸菌症 (NTM) :疾患の背景と概要

  • イントロダクション
  • 原因
  • 徴候と症状
  • 危険因子
  • 感染症の共通部位
  • 病態生理
  • 診断
  • 診断
  • 治療と管理

第5章 NTM患者への道のり

第6章 ケーススタディ

  • 米国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • 英国 (UK)
  • 日本

第7章 疫学と患者集団

  • 主な調査結果

第8章 主要7ヶ国のNTM感染症の総患者集団

第9章 NTM感染症の疫学

  • 米国
  • EU5ヶ国
  • 日本

第10章 アンメットニーズ

第11章 NTM感染症に貢献する組織

第12章 KOLの見解

第13章 付録

第14章 DelveInsightの機能

第15章 免責条項

第16章 DelveInsightについて

図表

List of Tables

  • Table 1 Demographics and sample sites of patients with less common nontuberculous mycobacteria species
  • Table 2 Clinical risk factors and outcomes of patients with isolation of non- Mycobacterium avium complex, non-Mycobacterium gordonae nontuberculous mycobacteria by site of isolation
  • Table 3 Clinical risk factors and outcomes in patients who met American Thoracic Society criteria for nontuberculous mycobacterial lung disease (not including patients with Mycobacterium avium complex) in comparison to those with isolation of Mycobacterium gordonae
  • Table 4 Primary and acquired immune deficiencies associated with disseminated NTM infection
  • Table 5 Treatment recommendations for slowly growing NTM
  • Table 6 Common Side Effects and Toxicities of Drugs Used For Therapy or Prophylaxis of Nontuberculous Mycobacterial Disease
  • Table 7 Treatment recommendations for rapidly growing NTM
  • Table 8 Prevalent Patient Population of Nontuberculous Mycobacteria (NTM) Infections in 7MM (2017-2030)
  • Table 9 Total Prevalent Cases of Nontuberculous Mycobacteria (NTM) Infections in the United States (2017-2030)
  • Table 10 Diagnosed Prevalent Cases of Nontuberculous Mycobacteria (NTM) Infections in the United States (2017-2030)
  • Table 11 Diagnosed Prevalent Cases of Nontuberculous Mycobacteria (NTM) by Species in the United States (2017-2030)
  • Table 12 Treatable Population of Nontuberculous Mycobacteria (NTM) Infections in the United States (2017-2030)
  • Table 13 Diagnosed Prevalent Cases of Nontuberculous Mycobacteria (NTM) Infections by Severity in the United States (2017-2030)
  • Table 14 Total Prevalent Cases of Nontuberculous Mycobacteria (NTM) Infections in Germany (2017-2030)
  • Table 15 Diagnosed Prevalent Cases of Nontuberculous Mycobacteria (NTM) Infections in Germany (2017-2030)
  • Table 16 Diagnosed Prevalent Cases of Nontuberculous Mycobacteria (NTM) by Species in Germany (2017-2030)
  • Table 17 Treatable Population of Nontuberculous Mycobacteria (NTM) Infections in Germany (2017-2030)
  • Table 18 Diagnosed Prevalent Cases of Nontuberculous Mycobacteria (NTM) Infections by Severity in Germany (2017-2030)
  • Table 19 Total Prevalent Cases of Nontuberculous Mycobacteria (NTM) Infections in France (2017-2030)
  • Table 20 Diagnosed Prevalent Cases of Nontuberculous Mycobacteria (NTM) Infections in France (2017-2030)
  • Table 21 Diagnosed Prevalent Cases of Nontuberculous Mycobacteria (NTM) by Species in France (2017-2030)
  • Table 22 Treatable Population of Nontuberculous Mycobacteria (NTM) Infections in France (2017-2030)
  • Table 23 Diagnosed Prevalent Cases of Nontuberculous Mycobacteria (NTM) Infections by Severity in France (2017-2030)
  • Table 24 Total Prevalent Cases of Nontuberculous Mycobacteria (NTM) Infections in Italy (2017-2030)
  • Table 25 Diagnosed Prevalent Cases of Nontuberculous Mycobacteria (NTM) Infections in Italy (2017-2030)
  • Table 26 Diagnosed Prevalent Cases of Nontuberculous Mycobacteria (NTM) by Species in Italy (2017-2030)
  • Table 27 Treatable Population of Nontuberculous Mycobacteria (NTM) Infections in Italy (2017-2030)
  • Table 28 Diagnosed Prevalent Cases of Nontuberculous Mycobacteria (NTM) Infections by Severity in Italy (2017-2030)
  • Table 29 Total Prevalent Cases of Nontuberculous Mycobacteria (NTM) Infections in Spain (2017-2030)
  • Table 30 Diagnosed Prevalent Cases of Nontuberculous Mycobacteria (NTM) Infections in Spain (2017-2030)
  • Table 31 Diagnosed Prevalent Cases of Nontuberculous Mycobacteria (NTM) by Species in Spain (2017-2030)
  • Table 32 Treatable Population of Nontuberculous Mycobacteria (NTM) Infections in Spain (2017-2030)
  • Table 33 Diagnosed Prevalent Cases of Nontuberculous Mycobacteria (NTM) Infections by Severity in Spain (2017-2030)
  • Table 34 Total Prevalent Cases of Nontuberculous Mycobacteria (NTM) Infections in the United Kingdom (2017-2030)
  • Table 35 Diagnosed Prevalent Cases of Nontuberculous Mycobacteria (NTM) Infections in the United Kingdom (2017-2030)
  • Table 36 Diagnosed Prevalent Cases of Nontuberculous Mycobacteria (NTM) by Species in the UK (2017-2030)
  • Table 37 Treatable Population of Nontuberculous Mycobacteria (NTM) Infections in the UK (2017-2030)
  • Table 38 Diagnosed Prevalent Cases of Nontuberculous Mycobacteria (NTM) Infections by Severity in the UK (2017-2030)
  • Table 39 Total Prevalent Cases of Nontuberculous Mycobacteria (NTM) Infections in Japan (2017-2030)
  • Table 40 Diagnosed Prevalent Cases of Nontuberculous Mycobacteria (NTM) Infections in Japan (2017-2030)
  • Table 41 Diagnosed Prevalent Cases of Nontuberculous Mycobacteria (NTM) by Species in Japan (2017-2030)
  • Table 42 Treatable Population of Nontuberculous Mycobacteria (NTM) Infections in Japan (2017-2030)
  • Table 43 Diagnosed Prevalent Cases of Nontuberculous Mycobacteria (NTM) Infections by Severity in Japan (2017-2030)
  • Table 44 Organizations contributing towards Nontuberculous Mycobacteria (NTM) Infections

List of Figures

  • Figure 1 Nontuberculous Mycobacteria (NTM) Infections subtypes
  • Figure 2 Mechanism of action of Botulinum toxin Type A
  • Figure 3 Treatment Algorithm of Nontuberculous Mycobacteria (NTM) Infections
  • Figure 4 Prevalent Patient Population of Nontuberculous Mycobacteria (NTM) Infections in 7MM (2017-2030)
  • Figure 5 Total Prevalent Cases of Nontuberculous Mycobacteria (NTM) Infections in the United States (2017-2030)
  • Figure 6 Diagnosed Prevalent Cases of Nontuberculous Mycobacteria (NTM) Infections in the United States (2017-2030)
  • Figure 7 Treatable Population of Nontuberculous Mycobacteria (NTM) Infections in the United States (2017-2030)
  • Figure 8 Diagnosed Prevalent Cases of Nontuberculous Mycobacteria (NTM) Infections by Severity in the United States (2017-2030)
  • Figure 9 Total Prevalent Cases of Nontuberculous Mycobacteria (NTM) Infections in Germany (2017-2030)
  • Figure 10 Diagnosed Prevalent Cases of Nontuberculous Mycobacteria (NTM) Infections in Germany (2017-2030)
  • Figure 11 Treatable Population of Nontuberculous Mycobacteria (NTM) Infections in Germany (2017-2030)
  • Figure 12 Diagnosed Prevalent Cases of Nontuberculous Mycobacteria (NTM) Infections by Severity in Germany (2017-2030)
  • Figure 13 Total Prevalent Cases of Nontuberculous Mycobacteria (NTM) Infections in France (2017-2030)
  • Figure 14 Diagnosed Prevalent Cases of Nontuberculous Mycobacteria (NTM) Infections in France (2017-2030)
  • Figure 15 Treatable Population of Nontuberculous Mycobacteria (NTM) Infections in France (2017-2030)
  • Figure 16 Diagnosed Prevalent Cases of Nontuberculous Mycobacteria (NTM) Infections by Severity in France (2017-2030)
  • Figure 17 Total Prevalent Cases of Nontuberculous Mycobacteria (NTM) Infections in Italy (2017-2030)
  • Figure 18 Diagnosed Prevalent Cases of Nontuberculous Mycobacteria (NTM) Infections in Italy (2017-2030)
  • Figure 19 Treatable Population of Nontuberculous Mycobacteria (NTM) Infections in Italy (2017-2030)
  • Figure 20 Diagnosed Prevalent Cases of Nontuberculous Mycobacteria (NTM) Infections by Severity in Italy (2017-2030)
  • Figure 21 Total Prevalent Cases of Nontuberculous Mycobacteria (NTM) Infections in Spain (2017-2030)
  • Figure 22 Diagnosed Prevalent Cases of Nontuberculous Mycobacteria (NTM) Infections in Spain (2017-2030)
  • Figure 23 Treatable Population of Nontuberculous Mycobacteria (NTM) Infections in Spain (2017-2030)
  • Figure 24 Diagnosed Prevalent Cases of Nontuberculous Mycobacteria (NTM) Infections by Severity in Spain (2017-2030)
  • Figure 25 Total Prevalent Cases of Nontuberculous Mycobacteria (NTM) Infections in the United Kingdom (2017-2030)
  • Figure 26 Diagnosed Prevalent Cases of Nontuberculous Mycobacteria (NTM) Infections in the United Kingdom (2017-2030)
  • Figure 27 Treatable Population of Nontuberculous Mycobacteria (NTM) Infections in the United Kingdom (2017-2030)
  • Figure 28 Diagnosed Prevalent Cases of Nontuberculous Mycobacteria (NTM) Infections by Severity in the United Kingdom (2017-2030)
  • Figure 29 Total Prevalent Cases of Nontuberculous Mycobacteria (NTM) Infections in Japan (2017-2030)
  • Figure 30 Diagnosed Prevalent Cases of Nontuberculous Mycobacteria (NTM) Infections in Japan (2017-2030)
  • Figure 31 Treatable Population of Nontuberculous Mycobacteria (NTM) Infections in Japan (2017-2030)
  • Figure 32 Diagnosed Prevalent Cases of Nontuberculous Mycobacteria (NTM) Infections by Severity in Japan (2017-2030)
  • Figure 33 Unmet Needs of Nontuberculous Mycobacteria (NTM) Infections
  • Figure 34 7 Major Market Size of Nontuberculous Mycobacteria (NTM) Infections in USD Million (2017-2030)
  • Figure 35 7 Major Market Size of Nontuberculous Mycobacteria (NTM) Infections by Therapies in USD Million (2017-2030)
  • Figure 36 Market Size of Nontuberculous Mycobacteria (NTM) Infections in the United States, USD Million (2017-2030)
  • Figure 37 The United States Market Size of Nontuberculous Mycobacteria (NTM) Infections by Therapies in USD Million (2017-2030)
  • Figure 38 Market Size of Nontuberculous Mycobacteria (NTM) Infections in Germany, USD Million (2017-2030)
  • Figure 39 Germany Market Size of Nontuberculous Mycobacteria (NTM) Infections by Therapies in USD Million (2017-2030)
  • Figure 40 Market Size of Nontuberculous Mycobacteria (NTM) Infections in France USD Million (2017-2030)
  • Figure 41 France Market Size of Nontuberculous Mycobacteria (NTM) Infections by Therapies in USD Million (2017-2030)
  • Figure 42 Market Size of Nontuberculous Mycobacteria (NTM) Infections in Italy, USD Million (2017-2030)
  • Figure 43 Italy Market Size of Nontuberculous Mycobacteria (NTM) Infections by Therapies in USD Million (2017-2030)
  • Figure 44 Market Size of Nontuberculous Mycobacteria (NTM) Infections in Spain, USD Million (2017-2030)
  • Figure 45 Spain Market Size of Nontuberculous Mycobacteria (NTM) Infections by Therapies in USD Million (2017-2030)
  • Figure 46 Market Size of Nontuberculous Mycobacteria (NTM) Infections in the United Kingdom, USD Million (2017-2030)
  • Figure 47 The United Kingdom Market Size of Nontuberculous Mycobacteria (NTM) Infections by Therapies in USD Million (2017-2030)
  • Figure 48 Market Size of Nontuberculous Mycobacteria (NTM) Infections in Japan, USD Million (2017-2030)
  • Figure 49 Japan Market Size of Nontuberculous Mycobacteria (NTM) Infections by Therapies in USD Million (2017-2030)
  • Figure 50 Market Drivers
  • Figure 51 Market Barriers
目次
Product Code: DIEI0438

DelveInsight's 'Nontuberculous Mycobacteria Infection (NTM) - Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical and forecasted Nontuberculous Mycobacteria Infection (NTM) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Nontuberculous Mycobacteria Infection (NTM) Understanding

Nontuberculous Mycobacteria Infection (NTM) is caused by nontuberculous mycobacteria which are ubiquitous, aerobic, non-motile, acid-fast bacteria commonly found in soil and water. Inhalation of these bacteria may cause disease in both healthy personnel and those with compromised immune systems.

The report covers the details of conventional and current medical therapies available in the NTM market for the treatment of the condition. It also provides the country-wise treatment guidelines and algorithm across the United States, Europe and Japan.

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030.

Nontuberculous Mycobacteria Infection (NTM) Epidemiology Perspective by DelveInsight

The Nontuberculous Mycobacteria Infection epidemiology division provide the insights about historical and current patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool, treatable patient pool and the prevalence based on various parameters such as species type and severity in the US, EU5 and Japan.

Key Findings

According to DelveInsight, the prevalent population of NTM in 7MM is expected to increase at a CAGR of 0.6% for the study period i.e. 2017-2030.

United States has the highest number of prevalent cases of NTM infections among all the 7MM countries.

According to a study by Wagner et al. (2014), the prevalence of PNTM in Europe ranged from 5.9 per 100,000 in Spain to 6.5 per 100,000 in the UK.

Nontuberculous Mycobacteria Infection (NTM) Detailed Epidemiology Segmentation

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total prevalent cases, total diagnosed prevalent cases, total treatable population, prevalence based on species, and prevalence based on severity) scenario of Nontuberculous Mycobacteria Infection in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017-2030.

The Nontuberculous Mycobacteria Infection report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

Scope of the Report

  • The NTM infections report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • The NTM infections epidemiology report and model provide an overview of the risk factors and global trends of NTM infections in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)
  • The report provides insight about the historical and forecasted patient pool of NTM infections in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) and Japan
  • The report assesses the disease risk and burden and highlights the unmet needs of the disease
  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population
  • The report assesses the disease risk and burden and highlights the unmet needs of NTM infections
  • The report provides the segmentation of the NTM epidemiology by species and severity in 7MM

Report Highlights

  • 10-year forecast of NTM infections epidemiology
  • 7MM coverage
  • Total prevalent cases of nontuberculous mycobacteria (NTM) infections
  • Diagnosed prevalent cases of nontuberculous mycobacteria (NTM) infections
  • Diagnosed prevalent cases of nontuberculous mycobacteria (NTM) infections by species
  • Treatable population of nontuberculous mycobacteria (NTM) infections
  • Diagnosed prevalent cases of nontuberculous mycobacteria (NTM) infections by severity

KOL- Views

We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to NTM infections?
  • What are the key findings pertaining to the NTM infections epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017-2030)?
  • What would be the total number of patients of NTM infections across the 7MM during the forecast period (2017-2030)?
  • Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017-2030)?
  • At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017-2030)?
  • What is the disease risk, burden and unmet needs of NTM infections?
  • What are the current available treatments of NTM infections?

Reasons to buy

The NTM infections epidemiology report will allow the user to -

  • Develop business strategies by understanding the trends shaping and driving the global NTM infections market
  • Quantify patient populations in the global NTM infections market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for NTM infections therapeutics in each of the markets covered
  • Understand the magnitude of NTM infections population by its age and gender groups
  • The NTM infections epidemiology report and model were written and developed by Masters and PhD level epidemiologists
  • The NTM infections epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 10-year forecast period using reputable sources

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

Table of Contents

1. Key Insights

2. Executive Summary

3. Nontuberculous Mycobacteria (NTM) Infections Market Overview At a Glance

  • 3.1. Patient Share (%) Distribution of Nontuberculous Mycobacteria (NTM) Infections in 2017
  • 3.2. Patient Share (%) Distribution of Nontuberculous Mycobacteria (NTM) Infections in 2030

4. Nontuberculous Mycobacteria (NTM): Disease Background and Overview

  • 4.1. Introduction
  • 4.2. Causes
  • 4.3. Sign and Symptoms
  • 4.4. Risk Factors
  • 4.5. Common sites of infection
  • 4.6. Pathophysiology
  • 4.7. Diagnosis
  • 4.8. Treatment and Management

5. NTM Patient Journey

6. Case Studies

  • 6.1. United States
  • 6.2. Germany
  • 6.3. France
  • 6.4. Italy
  • 6.5. Spain
  • 6.6. United Kingdom
  • 6.7. Japan

7. Epidemiology and Patient Population

  • 7.1. Epidemiology Key Findings

8. 7MM Total Prevalent Patient Population of Nontuberculous Mycobacteria (NTM) Infections

9. Epidemiology of Nontuberculous Mycobacteria (NTM) Infections

  • 9.1. United States
    • 9.1.1. Total Prevalent Cases of Nontuberculous Mycobacteria (NTM) Infections in the United States
    • 9.1.2. Diagnosed Prevalent Cases of Nontuberculous Mycobacteria (NTM) Infections in the United States
    • 9.1.3. Diagnosed Prevalent Cases of Nontuberculous Mycobacteria (NTM) by Species in the United States
    • 9.1.4. Treatable Population of Nontuberculous Mycobacteria (NTM) Infections in the United States
    • 9.1.5. Diagnosed Prevalent Cases of Nontuberculous Mycobacteria (NTM) Infections by Severity in the United States
  • 9.2. EU5
    • 9.2.1. Germany
    • 9.2.2. France
    • 9.2.3. Italy
    • 9.2.4. Spain
    • 9.2.5. The United Kingdom
  • 9.3. Japan
    • 9.3.1. Total Prevalent Cases of Nontuberculous Mycobacteria (NTM) Infections in Japan
    • 9.3.2. Diagnosed Prevalent Cases of Nontuberculous Mycobacteria (NTM) Infections in Japan
    • 9.3.3. Diagnosed Prevalent Cases of Nontuberculous Mycobacteria (NTM) by Species in Japan
    • 9.3.4. Treatable Population of Nontuberculous Mycobacteria (NTM) Infections in Japan
    • 9.3.5. Diagnosed Prevalent Cases of Nontuberculous Mycobacteria (NTM) Infections by Severity in Japan

10. Unmet Needs

11. Organizations contributing towards Nontuberculous Mycobacteria (NTM) Infections

12. KOL Views - Nontuberculous Mycobacteria (NTM) Infections

13. Appendix

  • 13.1. Bibliography
  • 13.2. Report Methodology

14. DelveInsight Capabilities

15. Disclaimer

16. About DelveInsight